Skip to Content Skip to Search
Woman Scientist working in the lab

About us

We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.

We have global businesses that research, develop and manufacture innovative pharmaceutical medicines and vaccines.

Our goal is to be one of the world’s most innovative, best performing and trusted healthcare companies.

What we do

We aim to bring differentiated, high-quality and needed healthcare products to as many people as possible, with our three global businesses, scientific and technical know-how and talented people.


Illustration of t-cells
Immune system T-cells attacking a cancer cell


Meningococcal serogroup B bacteria, commonly known as meningitis B
Meningococcal serogroup B bacteria, commonly known as meningitis B

How we do it

Everyone at GSK is focused on our 3 long-term priorities – Innovation, Performance, Trust, all powered by our performance-focused culture.


Innovation is at the heart of delivering GSK’s purpose, by using our science to develop better medicines, vaccines, and consumer healthcare products. We invest in scientific and technical excellence to develop and launch a pipeline of new products that meet the needs of patients, payers and consumers.

  • £4.3bn

    adjusted R&D investment in 2020

  • 40

    new medicines in development at FY 2020

  • 17

    new vaccines in development at FY 2020


We deliver growth by investing effectively in our business, developing our people and executing competitively.

  • £34bn

    turnover in 2020

  • £9bn

    adjusted operating profit in 2020

  • £5.4bn

    free cash flow in 2020

  • £4bn

    dividends paid in 2020


We are a responsible company – using our science and technology to address health needs, we are focused on making our products affordable and available and being a modern employer.

  • 84%

    employee engagement score on our latest employee survey

  • £250m

    donated in 2020 to community health programmes

  • 1st

    in Access to Medicines Index since the assessment began in 2008